Navigation Links
Rib-X Pharmaceuticals, Inc. Announces Formation of Clinical Advisory Board
Date:9/9/2008

NEW HAVEN, Conn., Sept. 9 /PRNewswire/ -- Rib-X Pharmaceuticals, Inc. ("Rib-X" or the "Company"), a development-stage company focused on the discovery and development of novel antibiotics for the treatment of antibiotic-resistant infections, announced today the formation of its Clinical Advisory Board. The Board, comprised of six infectious disease specialists, will provide oversight and counsel on matters related to the Company's clinical development programs.

Dr. Robert C. Moellering, Jr., M.D., will serve as Chairman of the Clinical Advisory Board. From 1999 to 2005, Dr. Moellering was the Herrman L. Blumgart Professor of Medicine at Harvard Medical School and Chairman of the Department of Medicine at Beth Israel Deaconess Medical Center, Boston. He now holds the Shields Warren-Mallinckrodt Chair of Medical Research at Harvard Medical School, and was the founder and served as the CEO of the Harvard Medical Faculty Physicians at Beth Israel Deaconess Medical Center until 2004.

Other individuals named to the Advisory Board include:

-- Helen W. Boucher, M.D., Assistant Professor of Medicine, Tufts University School of Medicine, Director of the Infectious Diseases Fellowship Program, and Staff Physician in the Division of Geographic Medicine and Infectious Diseases at Tufts Medical Center, Boston;

-- Henry F. Chambers, M.D., Chief Professor of Medicine in the Division of Infectious Diseases at San Francisco General Hospital, and the Director of the University of California, San Francisco Infectious Diseases Fellowship Training Program;

-- Barbara E. Murray, M.D., Director of the Division of Infectious Diseases at the University of Texas-Houston Medical School, and Co-Director of the UTHSC-H Center for the Study of Emerging and Re-Emerging Pathogens;

-- Leon G. Smith, M.D., Professor of Medicine and Preventive Medicine / Community Health at the University of Medicine and Dentistry of New Jersey, Chair of the Residency P
'/>"/>

SOURCE Rib-X Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Rib-X Pharmaceuticals to Present at Cambridge Healthtech Institutes 2nd Annual Challenge of Antibacterial Development Conference
2. Rib-X Pharmaceuticals Initiates Two Phase 2 Studies for Novel Antibiotic Compound RX-1741
3. VioQuest Pharmaceuticals, Inc Q2/08 Review Issued by Scimitar Equity, LLC
4. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
5. Kowa Company, Ltd. Acquires ProEthic Pharmaceuticals, Inc.
6. VioQuest Pharmaceuticals, Inc Valuation Upgrade Review Issued By Scimitar Equity, LLC
7. Pacira Pharmaceuticals, Inc. Adds Board Member and Key Senior Management
8. Alseres Pharmaceuticals, Inc. Raises $5 Million
9. Stason Pharmaceuticals, Inc. Appoints Diana Wood as Vice President, Business Development
10. Scimitar Equity, LLC Initiates Coverage Review of VioQuest Pharmaceuticals, Inc.
11. Renhuang Pharmaceuticals, Inc. Announces Solid Fourth Quarter and Fiscal Year 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... According to a new market ... PB/PK, PKPD, Trial Design, Toxicity Prediction, In-house, Contract Service), ... by End Users - Global Forecast to 2020", published ... USD 2,107.99 million by 2020 from USD 1,034.93 million ... Browse more than 75 ...
(Date:7/30/2015)... 30, 2015 Ascendis Pharma A/S (Nasdaq: ... its innovative TransCon technology to address significant unmet ... a six-month Phase 2 study to evaluate the ... in 53 treatment-naïve, pre-pubertal children with growth hormone ... pleased with the top-line results from our Phase ...
(Date:7/29/2015)... , July 30, 2015 ... results for the second quarter of 2015. CEO ... results and its performance in different businesses. ... http://www.eurobusinessmedia.com/ceo-direct/sanofi/sanofi-h1-2015-results-interview-with-ceo-olivier-brandicourt?utm_source=ceo-direct&utm_medium=wire Topics covered ... results - Performance drivers ...
(Date:7/29/2015)... , July 29, 2015 /PRNewswire/ - BioAmber Inc. (NYSE: ... the Company,s Chief Financial Officer has resigned.  The Company ... Financial Officer who retired in December 2014, as full ... a permanent successor.     Andy Ashworth ... and ensure a smooth transition.  Andy was the Company,s ...
Breaking Biology Technology:Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7BioAmber Announces Change in Chief Financial Officer 2BioAmber Announces Change in Chief Financial Officer 3
... Physicists at the University of California, Berkeley, have built the ... the diameter of a human hair that requires only a ... , The scientists successfully received their first FM broadcast last ... Boys, "Good Vibrations" transmitted from across the room. In homage ...
... 31 /PRNewswire-FirstCall/ - Dragon Pharmaceutical Inc.,(TSX: DDD; ... its biotech method,for 7ACA production has been ... believes this achievement validates the Company,s research,and ... This,technology would bring immediate benefits to production ...
... CRANBURY, N.J., Oct. 31 Amicus Therapeutics,(Nasdaq: ... small molecule,orally-active pharmacological chaperones for the treatment ... for the third quarter of 2007.,On a ... Generally Accepted,Accounting Principles (GAAP), Amicus announced a ...
Cached Biology Technology:World's smallest radio uses single nanotube to pick up good vibrations 2World's smallest radio uses single nanotube to pick up good vibrations 3World's smallest radio uses single nanotube to pick up good vibrations 4Dragon Announces R&D Achievement in Biotech Manufacturing Process 2Dragon Announces R&D Achievement in Biotech Manufacturing Process 3Amicus Therapeutics Announces Third Quarter 2007 Financial Results 2Amicus Therapeutics Announces Third Quarter 2007 Financial Results 3Amicus Therapeutics Announces Third Quarter 2007 Financial Results 4Amicus Therapeutics Announces Third Quarter 2007 Financial Results 5Amicus Therapeutics Announces Third Quarter 2007 Financial Results 6Amicus Therapeutics Announces Third Quarter 2007 Financial Results 7Amicus Therapeutics Announces Third Quarter 2007 Financial Results 8
(Date:7/21/2015)... , July 21, 2015 Today, ZTE ... Already received as well as expected revenues in 2015 that relate ... FPC,s communicated revenue guidance of approximately 2,200 MSEK for 2015. ... is a leading smartphone manufacturer in China ... FPC1 02 5 for Axon , ...
(Date:7/13/2015)... 13, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... company focused on the growing mobile commerce market, ... 62/188684 for BEHAVIORAL-DIRECTED AUTHENTIATION METHOD AND ... and secure method to make payments.  With this ... introduced with its groundbreaking voice-direct payment patent application, ...
(Date:7/8/2015)... , July 8, 2015 Summary Pancreatic ... the fourth most fatal, with a mortality rate of ... prognosis of pancreatic cancer patients has highlighted a significant ... is not being met by the current market. ... of products with varying molecule types and mechanisms of ...
Breaking Biology News(10 mins):FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3
... the University of Leeds, UK, the Charit University Medical ... Medicine (MDC) in Berlin, Germany, have discovered a new ... identified how ,junk, DNA promotes the growth of cancer ... (University of Leeds) and Dr Stephan Mathas (Charit, MDC) ...
... estimated that nearly 1.5 million Americans have been diagnosed with ... are believed to have some form of autism, according to ... and Prevention (CDC). Find out what new research and treatment ... ASD seen over the past few decades at a panel ...
... Heart and liver transplant recipients are at particularly ... donated organ, researchers report at the 2nd European Lung ... such cancers in these patients to maximize the chance ... for decades that the immunosuppressive drugs given to transplant ...
Cached Biology News:'Junk DNA' drives cancer growth 2Expert panel to discuss autism spectrum disorders 2Lung cancer risk particularly high for heart and liver transplant recipients 2
... PHD2000 syringe pump series combines Harvard Apparatuss best ... and a wide range of configuration options. A ... dimensions of syringes from all the major manufacturers. ... all the pertinent information from across the lab. ...
Mouse monoclonal antibody to RAD51L3 - RAD51-like 3 (S. cerevisiae)...
... you to store and manage very large ... secure central relational database. Storing and managing ... resource for clone tracking and enables you ... analysis. LabShare software integrates seamlessly with Invitrogen's ...
... A and Protein G bind specifically to ... A and Protein G conjugates are commonly ... (antibodies) and immunoglobulin subtypes from serum, hybridoma ... biological fluids. These reagents are also commonly ...
Biology Products: